Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.

Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.

Item

http://www.wikidata.org/entity/Q40725569

Q40725569

about

Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.

Item

http://www.wikidata.org/entity/Q40725569

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Evaluation of pharmacokinetic ...... study and simulation results.

@en

type

Item

label

Evaluation of pharmacokinetic ...... study and simulation results.

@en

prefLabel

Evaluation of pharmacokinetic ...... study and simulation results.

@en

P1476

Evaluation of pharmacokinetic ...... study and simulation results.

@en

P2093

Cheng Yao

http://www.w3.org/2001/XMLSchema#string

Dan Wang

http://www.w3.org/2001/XMLSchema#string

Jin Yang

http://www.w3.org/2001/XMLSchema#string

Qingqing Xiao

http://www.w3.org/2001/XMLSchema#string

Wanqiu Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

P304

133-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2016.1166532

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27052428

http://www.w3.org/2001/XMLSchema#string

Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.

about

Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698